Abstract
Adreno-cortical carcinoma (ACC) is a rare cancer with poor prognosis. Complete surgical resection of the primary tumor and, when feasible, of the local and distant metastases offers the best prospects for long-term survival; conversely, the role of systemic therapy in patients developing unresectable metastatic disease is unclear. We describe the case of a young female patient (36 yr) who presented with an androgen-releasing metastatic ACC. Treatment consisted of five courses of chemotherapy with etoposide, doxorubicin and cisplatin (EDP scheme) plus oral mitotane, which caused the complete disappearance of distant metastases and reduction of the primary tumor, as documented by serial computed tomography (CT) scans of the chest and the abdomen. Moreover, during treatment, clinical and biochemical resolution of the hypersecretory status occurred. The left adrenal gland was then removed and histopathological examination showed extensive tumor necrosis and the absence of viable cancer cells. The patient is currently alive without evidence of recurrence 3 yr after surgery. This report shows that chemotherapy plus mitotane could result in complete pathological remission, which may be a surrogate for long-term progression-free survival in metastatic ACC patients.
Similar content being viewed by others
References
Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for adrenal cortical carcinoma: analysis of a multiistitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996, 119: 161–70.
Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surgery 2001, 25: 891–7.
Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004, 60: 273–87.
Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322: 1195–201.
Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenal cortical carcinoma: a Southwest Oncology Group Study. Cancer 2000, 88: 1159–65.
Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adreno-cortical carcinoma. Br J Cancer 1998, 78: 546–9.
Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C. 5-fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991, 67: 2997–3000.
Van Slooten H, van Oosterom AT. CAP (cyclophosphamide, doxorubicin and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983, 67: 377–9.
Bukowski RM, Wolfe M, Levine HS. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma. A Southwest Oncology Group Study. J Clin Oncol 1993, 11: 161–5.
Villa R, Orlandi L, Berruti A, Dogliotti L, Zaffaroni N. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 1999, 14: 133–8.
Bates S, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991, 73: 18–29.
Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998, 83: 2194–200.
Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Related Cancer 2005, 12: 657–66.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sperone, P., Berruti, A., Gorzegno, G. et al. Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane. J Endocrinol Invest 29, 560–562 (2006). https://doi.org/10.1007/BF03344148
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344148